Multihance

Active Ingredient:: Gadobenate Dimeglumine
Origin:: EU

Multihance (Gadobenate Dimeglumine)

Q: What is Multihance used for?

Multihance is a gadolinium‑based contrast agent used to enhance magnetic resonance imaging. It improves the visibility of structures and lesions in brain, spine, liver, cardiac and vascular studies, helping radiologists obtain clearer diagnostic images.

Q: How does gadobenate dimeglumine work?

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. After intravenous injection it distributes in the extracellular space and accumulates in areas with high vascularity or disrupted barriers, producing brighter signals on T1‑weighted MRI scans.

Q: What is the usual dose of Multihance?

The dose of Multihance is determined by the prescribing physician based on the specific imaging protocol, patient weight, and renal function. The prescriber selects the appropriate volume and concentration to achieve optimal contrast enhancement for the intended MRI study.

Q: Is Multihance safe during pregnancy or breastfeeding?

Multihance is classified as pregnancy category C, meaning it should only be used when the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; a risk‑benefit assessment should be performed before administration to nursing mothers.

Q: How do I order Multihance from GNH India?

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Q: How does Multihance compare with other gadolinium contrast agents?

Multihance contains a gadolinium chelate with a higher relaxivity than many conventional agents, which can provide stronger signal enhancement at lower doses. Compared with agents such as gadopentetate dimeglumine, it may offer improved lesion conspicuity, especially in liver and cardiac imaging, while sharing a similar safety profile.

Q: How should Multihance be stored and handled?

Multihance should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Q: How is Multihance administered?

Multihance is administered intravenously as an injection solution. The prescribed volume is injected through a peripheral or central vein, typically using a power injector or manual bolus, immediately prior to the MRI scan according to the imaging protocol.

Q: What are the most serious risks to watch for with Multihance?

The most serious risks include nephrogenic systemic fibrosis in patients with severe renal impairment, severe allergic reactions such as anaphylaxis, and acute kidney injury. Clinicians should monitor renal function, observe patients for hypersensitivity, and be prepared to manage any severe adverse events.

Q: Who should not receive Multihance?

Multihance should be avoided in patients with known hypersensitivity to gadobenate dimeglumine or any component of the formulation, and in those with severe renal dysfunction (eGFR <30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis. Caution is also advised in pregnant or breastfeeding women.

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injection solution for intravenous use. It enhances magnetic resonance imaging by improving signal intensity in T1‑weighted scans of the brain, spine, liver, cardiovascular system and vascular structures.

GNH India supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bracco Imaging S.P.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Multihance (gadobenate dimeglumine) is used as a gadolinium‑based contrast agent to improve visualization in magnetic resonance imaging.

Brain MRI: enhances lesion detection and delineation.
Spine MRI: improves contrast of spinal cord and surrounding structures.
Liver MRI: provides better characterization of focal liver lesions.
Magnetic resonance angiography: increases vascular signal for clearer angiograms.
Cardiac MRI: facilitates assessment of myocardial perfusion and viability.

How It Works

Gadobenate dimeglumine is a paramagnetic gadolinium chelate that shortens the T1 relaxation time of nearby water protons. After intravenous injection, it distributes in the extracellular fluid and transiently accumulates in tissues with increased vascularity or disrupted blood‑brain barrier, producing higher signal intensity on T1‑weighted MRI sequences and thereby enhancing anatomical detail.

Side Effects

Adverse reactions to Multihance are generally related to its intravenous administration and the gadolinium chelate.

Common Side Effects

Nausea: mild to moderate feeling of stomach upset.
Injection site pain: transient discomfort at the infusion site.
Warmth sensation: brief feeling of heat or flushing during injection.

Serious or Rare Side Effects

Nephrogenic systemic fibrosis: fibrotic skin changes in patients with severe renal impairment.
Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention.
Acute kidney injury: rapid decline in renal function following exposure.
Cardiac arrest: rare but life‑threatening event.
Pulmonary edema: fluid accumulation in the lungs.
Severe hypotension: sudden drop in blood pressure.

Precautions & Warnings

When using Multihance, clinicians should observe several safety measures.

Renal function assessment: evaluate kidney function before use, especially in patients with eGFR <30 mL/min/1.73 m².
Pregnancy: category C, use only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding: consider discontinuing nursing or assess risk versus benefit.
History of allergic reactions: monitor for hypersensitivity during and after injection.
Concurrent gadolinium agents: avoid using multiple gadolinium contrast agents within 24 h.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Multihance may interact with other medicines or agents that affect renal function or cardiovascular response.

Major Interactions (Avoid)

Renal toxic agents: concurrent use with nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) may increase risk of NSF.
Other gadolinium agents: avoid administering another gadolinium‑based contrast within 24 h.
High‑dose iodinated contrast: may compound renal impairment.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may blunt heart‑rate response during stress MRI.
Diuretics: monitor fluid balance and renal function.
Chelating agents: may affect gadolinium clearance; observe for altered pharmacokinetics.

Frequently Asked Questions

Multihance is a gadolinium‑based contrast agent used to enhance magnetic resonance imaging. It improves the visibility of structures and lesions in brain, spine, liver, cardiac and vascular studies, helping radiologists obtain clearer diagnostic images.

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. After intravenous injection it distributes in the extracellular space and accumulates in areas with high vascularity or disrupted barriers, producing brighter signals on T1‑weighted MRI scans.

The dose of Multihance is determined by the prescribing physician based on the specific imaging protocol, patient weight, and renal function. The prescriber selects the appropriate volume and concentration to achieve optimal contrast enhancement for the intended MRI study.

Multihance is classified as pregnancy category C, meaning it should only be used when the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; a risk‑benefit assessment should be performed before administration to nursing mothers.

To order Multihance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Multihance contains a gadolinium chelate with a higher relaxivity than many conventional agents, which can provide stronger signal enhancement at lower doses. Compared with agents such as gadopentetate dimeglumine, it may offer improved lesion conspicuity, especially in liver and cardiac imaging, while sharing a similar safety profile.

Multihance should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Multihance is administered intravenously as an injection solution. The prescribed volume is injected through a peripheral or central vein, typically using a power injector or manual bolus, immediately prior to the MRI scan according to the imaging protocol.

The most serious risks include nephrogenic systemic fibrosis in patients with severe renal impairment, severe allergic reactions such as anaphylaxis, and acute kidney injury. Clinicians should monitor renal function, observe patients for hypersensitivity, and be prepared to manage any severe adverse events.

Multihance should be avoided in patients with known hypersensitivity to gadobenate dimeglumine or any component of the formulation, and in those with severe renal dysfunction (eGFR <30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis. Caution is also advised in pregnant or breastfeeding women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.